资源描述：
《Navidea_Annual_Report_2012_web_ready》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、enlighteningempoweringenhancing2012ANNUALREPORTenlighteningempoweringenhancingFinancialHighlights
2、Amountsinthousands,exceptpersharedataYearsEndedDecember31,20122011201020092008Revenue$79$598$617$--$--Operatingexpenses28,06824,70213,2947,4086,692Lossfromoperations(27,989)(24,104)(12,677
3、)(7,408)(6,692)Income(loss)attributable(29,201)5,513(58,172)(39,846)(5,166)tocommonstockholdersBasicincome(loss)pershare(0.29)0.06(0.72)(0.54)(0.08)AsofDecember31,20122011201020092008Totalassets$11,972$31,194$10,863$9,018$9,619Stockholders’equity(deficit)(1,405)21,1324,132(9,870)(3,026
4、)enlighteningempoweringenhancingAyearofmilestoneachievementsforpatients,physiciansandshareholdersToOurValuedShareholders,ThispastyearhasmarkedamomentousperiodforNavideaBiopharmaceuticals.Atthecoreofourperformancethroughouttheyear,webroughtLymphoseek®,thefirstnewdiagnosticagentforlympha
5、ticmappingin30yearsandthefirstprecisiondiagnostic,throughtheU.S.FoodandDrugAdministration(FDA)approvalprocessandtopatientswithbreastcancerandmelanoma.Moreover,weadvancedourleadershippositionininnovativeprecisiondiagnosticsonseveralfronts:weadvancedourdevelopmentpipelineforlargeandgrowi
6、ngmarketsinoncologyandneurodegenerativediseases;weenhancedourinternalcapabilitieswiththeadditionofkeypersonnelincommercial,clinical,regulatory,manufacturingandmanagement;andwemetourfinancialcommitmentsandsecuredflexibleaccesstomultipleavailablefundingsourcestosupportourgrowthaswellasgr
7、ewourinstitutionalinvestorshareholderbase.Webelievetheseaccomplishmentslaythefoundationforvalueenhancementtoourshareholders.Followingareafewhighlights.Lymphoseek&OncologyPrograms•IntheU.S.,Lymphoseek,ourfirstprecisiondiagnostic,wasapprovedbytheFDAinMarch2013.Lymphoseek®(technetiumTc99m
8、tilmanocept)Injectionisindicatedforuseinlymphaticmappingprocedurestohelpinthediagnosticevaluationofpotentialcancerspreadforpatientswithbreastcancerandmelanoma.TheU.S.launchofLymphoseekbeganinMay2013withsalesanddistributionthroughtheextensivenetworkofmorethan140nuclearpharmaciesoperat
